CSL
CSL Ltd
Biotechnology
·
Healthcare
92
comments
41
fund managers
past 90 days
About CSL Ltd
CSL Ltd. is a global biopharmaceutical company headquartered in Melbourne, Australia, founded in 1961. The firm develops, manufactures, and distributes biopharmaceutical products across three primary business segments: CSL Behring, focusing on plasma-derived therapies, gene therapies, and recombinants; CSL Seqirus, specializing in influenza vaccines and government pandemic services; and CSL Vifor, targeting therapeutic areas including iron deficiency and nephrology. CSL operates as a key player in the healthcare sector, integrating research and development with global commercial distribution to deliver specialized medical treatments.
Commentary Volume
92
Comments
41
Fund managers
0
Past 90 days
SOURCE
ACTION
COMMENT PREVIEW
FUND MANAGER
DATE
Loading...
.
​Loading...
Loading...
Loading...
Loading...
Source: Ipsum Capital Q4 Quarterly Letter · Published 14 March 2025
Report a problem
Loading...
.
Loading...
Loading...
Loading...
Loading...
§ Important Notice
The entries below are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Commentary
Sector
Healthcare
Market cap
$47B
Fund managers
41 managers
First covered
31 Mar 2023
Last updated
18 May 2026
Company Details
Related Themes
ic
Ipsum Capital
6 comments
ic
Amet Funds
4 comments
ic
Dolor
3 comments
Top Investors Covering MIN
§ Reminder
The entries above are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Frequently asked questions about CSL Ltd (ASX:CSL)
Frequently asked questions
Who is investing in CSL Ltd (ASX:CSL)?
Fund managers including Cooper Investors, Oracle Advisory Group, Equity Trustees Asset Management, Maple-Brown Abbott, Pendal Group, Yarra Capital Management, Clime Investment Management, Alliance Bernstein, SG Hiscock & Company, Wilson Asset Management, Flagship Investments, Blackwattle Investment Partners, Milford Asset Management, Ten Cap, Infinity Asset Management, Tyndall Asset Management, Seneca Financial Solutions, Hyperion Asset Management, Elston Asset Management, ECP Asset Management, Airlie Funds Management, Selector Funds Management, Sage Capital, Prime Value Asset Management, Perpetual Asset Management, Sterling Managed Investments, Atlas Funds Management, Perennial Partners, ELM Responsible Investments, Platypus Asset Management, Pengana Capital Group, ClearBridge Investments, Investors Mutual Limited, Allan Gray, Ausbil Investment Management, IML Equity Income Fund, Greencape Capital, Ellerston Capital, Antares Capital, Katana Asset Management and Paradice Investment Management have invested in CSL Ltd (ASX:CSL).
What is the short interest in CSL Ltd (ASX:CSL)?
The short interest in CSL Ltd (ASX:CSL) is 0.47% which makes it the 284th most shorted stock on the ASX. Of the 485.2M shares that CSL Ltd has on issue, 2.3M have been sold short.
What does CSL Ltd (ASX:CSL) do?
CSL Ltd. is a global biopharmaceutical company headquartered in Melbourne, Australia, founded in 1961. The firm develops, manufactures, and distributes biopharmaceutical products across three primary business segments: CSL Behring, focusing on plasma-derived therapies, gene therapies, and recombinants; CSL Seqirus, specializing in influenza vaccines and government pandemic services; and CSL Vifor, targeting therapeutic areas including iron deficiency and nephrology. CSL operates as a key player in the healthcare sector, integrating research and development with global commercial distribution to deliver specialized medical treatments.
Loading...